You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泽璟制药(688266.SH):获批开展甲苯磺酸多纳非尼片与KN046注射液联合治疗晚期消化道实体瘤的临床试验
格隆汇 08-04 15:40

格隆汇 8 月 4日丨泽璟制药(688266.SH)公布,公司收到国家药品监督管理局(国家药监局)核准签发的药物临床试验批准通知书》

此次获批开展甲苯磺酸多纳非尼片KN046射液联合治疗晚期消化道实体瘤的临床试验根据《Clinical Development Success Rates 2006-2015》公布的数据,对于抗肿瘤药物,一般I/II期临床研究阶段持续约2 年时间,I期完成进II期的比率约62.8%II期完成进入III期的比率约24.6%。由于药品的研发周期长、审批环节多、研发投入大,容易受到一些不确定性因素的影响,敬请广大投资者谨慎决策,注意防范投资风险

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account